Hemenway Trust Hemenway Trust’s Apimeds Pharmaceuticals US APUS Stock Holding History

Hemenway Trust Hemenway Trust’s Portfolio APUS Stock Details APUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$247K	Hold	27,400	–	–	0.02%	124
2026 Q1	$490K	Hold	27,400	–	–	0.04%	81
2025 Q4	$449K	Buy	27,400 +2,400	+10%	+$51.2K	0.03%	87
2025 Q3	$445K	Buy	+25,000	New	+$463K	0.03%	88

Other funds holding APUS

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Hemenway Trust Hemenway Trust's APUS Position: Q2 2026 in Review

Hemenway Trust Hemenway Trust held its Apimeds Pharmaceuticals US (APUS) position steady in Q2 2026 at 27,400 shares worth $247K. The position accounts for 0.02% of the portfolio, ranked #124.

Hemenway Trust Hemenway Trust first reported a position in APUS in Q3 2025 and has held it in 4 quarters since. The position peaked at $490K in Q1 2026. 7 funds tracked by Wall St. Rank hold APUS as of Q2 2026.

Hemenway Trust Hemenway Trust held 27,400 shares of Apimeds Pharmaceuticals US worth $247K as of Q2 2026.
Hemenway Trust Hemenway Trust left its Apimeds Pharmaceuticals US share count unchanged in Q2 2026.
Apimeds Pharmaceuticals US made up 0.02% of Hemenway Trust Hemenway Trust's portfolio in Q2 2026, its #124 holding.
Hemenway Trust Hemenway Trust first reported a position in Apimeds Pharmaceuticals US in Q3 2025 and has held it in 4 quarters since.
Hemenway Trust Hemenway Trust's Apimeds Pharmaceuticals US position peaked at $490K in Q1 2026.
7 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q2 2026.

Based on Hemenway Trust Hemenway Trust's 13F filing for Q2 2026, filed 11 Aug 2026.